Loading data
XENENasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development expense | 300.94 m USD | 210.39 m USD | 167.51 m USD | 105.77 m USD | 75.46 m USD |
| Operating profit | -373.07 m USD | -279.3 m USD | -214.05 m USD | -129.14 m USD | -78.99 m USD |
| Profit before tax | -344.89 m USD | -238.42 m USD | -182.69 m USD | -125.26 m USD | -78.89 m USD |
| Income tax expense | 1.02 m USD | -4.09 m USD | -292 k USD | 118 k USD | -6 k USD |
| Net income (reported basis) | -345.91 m USD | -234.33 m USD | -182.39 m USD | -125.37 m USD | -78.88 m USD |
| Net income attributable to common shareholders | — | -234.33 m USD | -182.39 m USD | -124.94 m USD | -77.09 m USD |
| Basic earnings per share | -4.36 USD/share | -3.01 USD/share | -2.73 USD/share | -2.06 USD/share | -1.77 USD/share |
| Diluted earnings per share | -4.36 USD/share | -3.01 USD/share | -2.73 USD/share | -2.06 USD/share | -1.77 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.